(NASDAQ: BLUE) Bluebird Bio's forecast annual revenue growth rate of 139.79% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Bluebird Bio's revenue in 2024 is $21,726,000.On average, 6 Wall Street analysts forecast BLUE's revenue for 2024 to be $14,344,910,883, with the lowest BLUE revenue forecast at $10,754,309,714, and the highest BLUE revenue forecast at $18,313,815,343. On average, 5 Wall Street analysts forecast BLUE's revenue for 2025 to be $23,292,549,047, with the lowest BLUE revenue forecast at $19,692,544,963, and the highest BLUE revenue forecast at $26,108,612,497.
In 2026, BLUE is forecast to generate $33,279,755,904 in revenue, with the lowest revenue forecast at $33,279,755,904 and the highest revenue forecast at $33,279,755,904.